

Nigel H Greig

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3847583/nigel-h-greig-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

247
papers

15,336
citations

68
h-index

115
g-index

268
ext. papers

17,616
ext. citations

5.7
avg, IF

6.49
L-index

#	Paper	IF	Citations
247	Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.. <i>Neurotherapeutics</i> , 2022 , 1	6.4	0
246	and Analyses of the Inhibitory Action of the Alzheimer Drug Posiphen and Primary Metabolites with Human Acetyl- and Butyrylcholinesterase Enzymes.. <i>ACS Pharmacology and Translational Science</i> , 2022 , 5, 70-79	5.9	0
245	Diphtheria toxin induced but not CSF1R inhibitor mediated microglia ablation model leads to the loss of CSF/ventricular spaces in vivo that is independent of cytokine upregulation.. <i>Journal of Neuroinflammation</i> , 2022 , 19, 3	10.1	1
244	Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	1
243	3,6?- and 1,6?-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation. <i>Pharmaceutics</i> , 2022 , 14, 950	6.4	0
242	Age-related impairment of cerebral blood flow response to K channel opener in Alzheimer's disease mice with presenilin-1 mutation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 41, 1579-1591	7.3	4
241	Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders. <i>Frontiers in Neuroscience</i> , 2021 , 15, 656921	5.1	6
240	-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge. <i>ACS Pharmacology and Translational Science</i> , 2021 , 4, 980-1000	5.9	4
239	Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment. <i>Frontiers in Psychiatry</i> , 2021 , 12, 536257	5	15
238	Thionation of Aminophthalimide Hindered Carbonyl Groups and Application to the Synthesis of 3,6?-Dithionated Pomalidomides. <i>Synlett</i> , 2021 , 32, 917-922	2.2	1
237	Neuronal and Astrocytic Extracellular Vesicle Biomarkers in Blood Reflect Brain Pathology in Mouse Models of Alzheimer's Disease. <i>Cells</i> , 2021 , 10,	7.9	7
236	High Throughput Virtual Screening and Molecular Dynamics Simulation for Identifying a Putative Inhibitor of Bacterial CTX-M-15. <i>Antibiotics</i> , 2021 , 10,	4.9	5
235	nAChRs gene expression and neuroinflammation in APPswe/PS1dE9 transgenic mouse. <i>Scientific Reports</i> , 2021 , 11, 9711	4.9	1
234	Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. <i>ACS Pharmacology and Translational Science</i> , 2021 , 4, 858-869	5.9	4
233	3,6'-Dithiopomalidomide Ameliorates Hippocampal Neurodegeneration, Microgliosis and Astroglia and Improves Cognitive Behaviors in Rats with a Moderate Traumatic Brain Injury. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
232	The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration. <i>Journal of Neurochemistry</i> , 2021 , 159, 867-886	6	0
231	Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs. <i>Molecules</i> , 2020 , 25,	4.8	4

230	Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 595-602	5.9	15
229	Neuroprotection by the Immunomodulatory Drug Pomalidomide in the LRRK2 Genetic Model of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020 , 12, 31	5.3	7
228	Rivastigmine modifies the β-secretase pathway and potentially early Alzheimer's disease. <i>Translational Psychiatry</i> , 2020 , 10, 47	8.6	25
227	Post-treatment with Posiphen Reduces Endoplasmic Reticulum Stress and Neurodegeneration in Stroke Brain. <i>IScience</i> , 2020 , 23, 100866	6.1	5
226	3,6'-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation. <i>ELife</i> , 2020 , 9,	8.9	13
225	Time-dependent cytokine and chemokine changes in mouse cerebral cortex following a mild traumatic brain injury. <i>ELife</i> , 2020 , 9,	8.9	11
224	Traumatic brain injury increases plasma astrocyte-derived exosome levels of neurotoxic complement proteins. <i>FASEB Journal</i> , 2020 , 34, 3359-3366	0.9	31
223	Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury. <i>Experimental Neurology</i> , 2020 , 324, 113113	5.7	5
222	(-)-Phenserine tartrate (PhenT) as a treatment for traumatic brain injury. <i>CNS Neuroscience and Therapeutics</i> , 2020 , 26, 636-649	6.8	7
221	The p53 inactivators pifithrin-β and pifithrin-β mitigate TBI-induced neuronal damage through regulation of oxidative stress, neuroinflammation, autophagy and mitophagy. <i>Experimental Neurology</i> , 2020 , 324, 113135	5.7	20
220	PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2020 , 14, 785	5.1	9
219	Neuronal Hyperexcitability Following mTBI 2019 , 67-81		
218	Post-Injury Neuroprotective Effects of the Thalidomide Analog 3,6'-Dithiothalidomide on Traumatic Brain Injury. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
217	(-)-Phenserine Ameliorates Contusion Volume, Neuroinflammation, and Behavioral Impairments Induced by Traumatic Brain Injury in Mice. <i>Cell Transplantation</i> , 2019 , 28, 1183-1196	4	7
216	Is insulin resistance the cause of fibromyalgia? A preliminary report. <i>PLoS ONE</i> , 2019 , 14, e0216079	3.7	4
215	Pifithrin-Alpha Reduces Methamphetamine Neurotoxicity in Cultured Dopaminergic Neurons. <i>Neurotoxicity Research</i> , 2019 , 36, 347-356	4.3	8
214	Pomalidomide Reduces Ischemic Brain Injury in Rodents. <i>Cell Transplantation</i> , 2019 , 28, 439-450	4	9
213	Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide. <i>Future Medicinal Chemistry</i> , 2019 , 11, 489-493	4.1	16

212	Can We Prevent Dementia and Not Prevent Neurons from Dying?. <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 489-492	4.3	2
211	Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. <i>ACS Pharmacology and Translational Science</i> , 2019 , 2, 66-91	5.9	15
210	Mitophagy inhibits amyloid- β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. <i>Nature Neuroscience</i> , 2019 , 22, 401-412	25.5	546
209	Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid- β Pathology in Female Rhesus Macaques (<i>Macaca Mulatta</i>). <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 115-126	4.3	6
208	Neuronal Enriched Extracellular Vesicle Proteins as Biomarkers for Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019 , 36, 975-987	5.4	25
207	(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice. <i>Neurobiology of Disease</i> , 2019 , 130, 104528	7.5	22
206	Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 1818-1830	7	26
205	A Pilot Study of Exenatide Actions in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2019 , 16, 741-752	3	30
204	Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury. <i>Frontiers in Cell and Developmental Biology</i> , 2019 , 7, 356	5.7	14
203	Microbes and Monoamines: Potential Neuropsychiatric Consequences of Dysbiosis. <i>Trends in Neurosciences</i> , 2019 , 42, 151-163	13.3	12
202	Geriatric pharmacotherapy: Appraising new drugs for neurologic disorders in older patients. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2019 , 167, 3-18	3	1
201	Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon. <i>Scientific Reports</i> , 2019 , 9, 17208	4.9	9
200	Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. <i>Frontiers in Cell and Developmental Biology</i> , 2019 , 7, 313	5.7	49
199	Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury. <i>Neurobiology of Disease</i> , 2019 , 124, 439-453	7.5	16
198	Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. <i>JAMA Neurology</i> , 2019 , 76, 420-429	17.2	95
197	Neuroprotective effects of pifithrin- α against traumatic brain injury in the striatum through suppression of neuroinflammation, oxidative stress, autophagy, and apoptosis. <i>Scientific Reports</i> , 2018 , 8, 2368	4.9	41
196	Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimides for nitrite, TNF- α and angiogenesis inhibitory activities. <i>Bioorganic and Medicinal Chemistry</i> , 2018 , 26, 1547-1559	3.4	9
195	Sequential combined Treatment of Pifithrin- α and Posiphen Enhances Neurogenesis and Functional Recovery After Stroke. <i>Cell Transplantation</i> , 2018 , 27, 607-621	4	4

194	The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials. <i>Genes</i> , 2018 , 9,	4.2	58
193	Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease. <i>Scientific Reports</i> , 2018 , 8, 10722	4.9	27
192	Neuroinflammation and ER-stress are key mechanisms of acute bilirubin toxicity and hearing loss in a mouse model. <i>PLoS ONE</i> , 2018 , 13, e0201022	3.7	18
191	(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2018 , 15, 883-891	3	11
190	GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, OR6-4	0	
189	Inhibition of butyrylcholinesterase improves prepulse inhibition deficits and enhances M1 muscarinic acetylcholine receptor-mediated responses via ghrelin signaling in mice. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, PO1-1-134	0	
188	Posiphen is a new experimental drug to understand and mitigate age-related neurodegenerative disorders. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, SY54-3	0	
187	Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?. <i>Alzheimer's and Dementia</i> , 2018 , 14, 431-443	1.2	25
186	P3-061: CONSTITUTIVE IN VIVO OVEREXPRESSION OF MIR146A AND MIR200B INDEPENDENTLY MODULATES LEVELS OF ALZHEIMER'S DISEASE (AD)- RELATED PROTEINS IN THE MOUSE HIPPOCAMPUS AND CEREBRAL CORTEX 2018 , 14, P1088-P1088		
185	Role of viruses, prions and miRNA in neurodegenerative disorders and dementia. <i>VirusDisease</i> , 2018 , 29, 419-433	3.4	6
184	P3-053: (-)-PHENSERINE (PHEN) AND THE PREVENTION OF PRE-PROGRAMMED CELL DEATH IN ALZHEIMER'S DISEASE (AD) AND MILD TRAUMATIC BRAIN INJURY (MTBI) 2018 , 14, P1083-P1083		
183	Pomalidomide Ameliorates H ₂ O ₂ -Induced Oxidative Stress Injury and Cell Death in Rat Primary Cortical Neuronal Cultures by Inducing Anti-Oxidative and Anti-Apoptosis Effects. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	16
182	Glucose-Dependent Insulinotropic Polypeptide Mitigates 6-OHDA-Induced Behavioral Impairments in Parkinsonian Rats. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	9
181	Novel GLP-1R/GIPR co-agonist "twincretin" is neuroprotective in cell and rodent models of mild traumatic brain injury. <i>Experimental Neurology</i> , 2017 , 288, 176-186	5.7	27
180	Mitophagy and Alzheimer's Disease: Cellular and Molecular Mechanisms. <i>Trends in Neurosciences</i> , 2017 , 40, 151-166	13.3	330
179	Dopaminergic Neuron-Specific Deletion of p53 Gene Attenuates Methamphetamine Neurotoxicity. <i>Neurotoxicity Research</i> , 2017 , 32, 218-230	4.3	9
178	Insulin resistance and exendin-4 treatment for multiple system atrophy. <i>Brain</i> , 2017 , 140, 1420-1436	11.2	50
177	(-)-Phenserine inhibits neuronal apoptosis following ischemia/reperfusion injury. <i>Brain Research</i> , 2017 , 1677, 118-128	3.7	26

176	Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine. <i>Journal of Biomedical Science</i> , 2017 , 24, 71	13.3	21
175	Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration. <i>Scientific Reports</i> , 2017 , 7, 3735	4.9	29
174	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017 , 390, 1664-1675	40	352
173	Are pulmonary fibrosis and Alzheimer's disease linked? Shared dysregulation of two miRNA species and downstream pathways accompany both disorders. <i>Journal of Biological Chemistry</i> , 2017 , 292, 20353	5.4	4
172	Drug discovery and development: Role of basic biological research. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 651-657	6	178
171	A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. <i>Cell Transplantation</i> , 2017 , 26, 1560-1571	4	66
170	Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke. <i>Experimental Neurology</i> , 2017 , 288, 104-113	5.7	18
169	A Bayesian Model for the Prediction and Early Diagnosis of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 77	5.3	34
168	Adiponectin as a Potential Therapeutic Target for Prostate Cancer. <i>Current Pharmaceutical Design</i> , 2017 , 23, 4170-4179	3.3	20
167	Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview. <i>Current Alzheimer Research</i> , 2017 , 14, 1190-1197	3	26
166	Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective. <i>Current Alzheimer Research</i> , 2017 , 14, 1164-1181	3	36
165	Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017 , 16, 820-827	2.6	13
164	Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4. <i>Alzheimer's and Dementia</i> , 2016 , 12, 34-48	1.2	38
163	Post-traumatic administration of the p53 inactivator pifithrin- α oxygen analogue reduces hippocampal neuronal loss and improves cognitive deficits after experimental traumatic brain injury. <i>Neurobiology of Disease</i> , 2016 , 96, 216-226	7.5	26
162	Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory Function. <i>Cell Metabolism</i> , 2016 , 24, 332-40	24.6	243
161	Novel pharmaceutical treatments for minimal traumatic brain injury and evaluation of animal models and methodologies supporting their development. <i>Journal of Neuroscience Methods</i> , 2016 , 272, 69-76	3	15
160	Mild traumatic brain injury-induced hippocampal gene expressions: The identification of target cellular processes for drug development. <i>Journal of Neuroscience Methods</i> , 2016 , 272, 4-18	3	17
159	Transgenerational latent early-life associated regulation unites environment and genetics across generations. <i>Epigenomics</i> , 2016 , 8, 373-87	4.4	14

158	Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms. <i>PLoS ONE</i> , 2016 , 11, e0156493	3.7	31
157	In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. <i>Oncotarget</i> , 2016 , 7, 33237-45	3.3	29
156	Neuroprotective Mechanisms Mediated by CDK5 Inhibition. <i>Current Pharmaceutical Design</i> , 2016 , 22, 527-34	3.3	35
155	Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. <i>Current Pharmaceutical Design</i> , 2016 , 22, 4360-4373	3.3	39
154	miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease. <i>Medicinal Chemistry</i> , 2016 , 12, 217-25	1.8	47
153	Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. <i>Journal of Neuroinflammation</i> , 2016 , 13, 168	10.1	28
152	Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model. <i>Journal of Neurochemistry</i> , 2016 , 138, 746-57	6	28
151	Neuroinflammation in animal models of traumatic brain injury. <i>Journal of Neuroscience Methods</i> , 2016 , 272, 38-49	3	140
150	Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats. <i>Journal of Neurotrauma</i> , 2016 , 33, 2044-2054	5.4	26
149	What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?. <i>Lancet Psychiatry</i> , 2015 , 2, 756-764	23.3	11
148	Transiently lowering tumor necrosis factor- β synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice. <i>Journal of Neuroinflammation</i> , 2015 , 12, 45	10.1	87
147	Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. <i>Experimental Neurology</i> , 2015 , 273, 151-60	5.7	35
146	miRNAs: Key Players in Neurodegenerative Disorders and Epilepsy. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 563-80	4.3	78
145	Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. <i>Journal of Neurochemistry</i> , 2015 , 135, 1203-1217	6	58
144	Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. <i>Current Alzheimer Research</i> , 2015 , 12, 32-46	3	192
143	A new roadmap for drug development for Alzheimer's disease. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 156	64.1	43
142	Critical role of TNF- β in cerebral aneurysm formation and progression to rupture. <i>Journal of Neuroinflammation</i> , 2014 , 11, 77	10.1	78
141	Amyloid- β precursor protein synthesis inhibitors for Alzheimer's disease treatment. <i>Annals of Neurology</i> , 2014 , 76, 629-30	9.4	4

140	(-)-Phenserine attenuates soman-induced neuropathology. <i>PLoS ONE</i> , 2014 , 9, e99818	3.7	14
139	Neuronal cellular responses to extremely low frequency electromagnetic field exposure: implications regarding oxidative stress and neurodegeneration. <i>PLoS ONE</i> , 2014 , 9, e104973	3.7	43
138	Lessons from a BACE1 inhibitor trial: off-site but not off base. <i>Alzheimer's and Dementia</i> , 2014 , 10, S411-9.2		54
137	Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. <i>Alzheimer's and Dementia</i> , 2014 , 10, S62-75	1.2	58
136	Evidence of a novel mechanism for partial β -secretase inhibition induced paradoxical increase in secreted amyloid β protein. <i>PLoS ONE</i> , 2014 , 9, e91531	3.7	16
135	Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid- β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway. <i>Current Alzheimer Research</i> , 2014 , 11, 608-22	3	37
134	A new regulatory road-map for Alzheimer's disease drug development. <i>Current Alzheimer Research</i> , 2014 , 11, 215-20	3	11
133	Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 338-46	2.6	16
132	Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1280-93	2.6	81
131	Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1432-9	2.6	137
130	Exploring N(1)-p-fluorobenzyl-cymserine as an inhibitor of 5-lipoxygenase as a candidate for type 2 diabetes and neurodegenerative disorder treatment. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 197-202	2.6	0
129	Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. <i>Age</i> , 2013 , 35, 1621-36		65
128	Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury. <i>Neurobiology of Disease</i> , 2013 , 54, 1-11	7.5	69
127	TNF- β induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013 , 33, 1564-73	7.3	105
126	Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. <i>Experimental Neurology</i> , 2013 , 239, 170-82	5.7	70
125	Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?. <i>Alzheimer's and Dementia</i> , 2013 , 9, 50-7	1.2	23
124	3,6'-dithiothalidomide improves experimental stroke outcome by suppressing neuroinflammation. <i>Journal of Neuroscience Research</i> , 2013 , 91, 671-80	4.4	33
123	Reply to D'Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, E4820	11.5	5

122	Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 12703-8	11.5	47
121	Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease. <i>PLoS ONE</i> , 2013 , 8, e54887	3.7	46
120	Cognitive impairments accompanying rodent mild traumatic brain injury involve p53-dependent neuronal cell death and are ameliorated by the tetrahydrobenzothiazole PFT- μ . <i>PLoS ONE</i> , 2013 , 8, e79837	3.7	58
119	Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. <i>PLoS ONE</i> , 2013 , 8, e82016	3.7	48
118	Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid- β levels. <i>PLoS ONE</i> , 2013 , 8, e58752	3.7	30
117	New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors. <i>Recent Patents on CNS Drug Discovery</i> , 2013 , 8, 123-41		23
116	Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, β synuclein synthesis, interleukin-1 β release, and cholinergic action. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2013 , 12, 117-28	2	19
115	Molecular interaction study of N1-p-fluorobenzyl-cymserine with TNF- β p38 kinase and JNK kinase. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2013 , 12, 129-35	2	6
114	Exendin-4 decreases amphetamine-induced locomotor activity. <i>Physiology and Behavior</i> , 2012 , 106, 574-8	3.5	66
113	TNF- β protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. <i>Journal of Neuroinflammation</i> , 2012 , 9, 23	10.1	197
112	Acetylcholinesterase inhibition ameliorates deficits in motivational drive. <i>Behavioral and Brain Functions</i> , 2012 , 8, 15	4.1	10
111	Roles of p75(NTR), long-term depression, and cholinergic transmission in anxiety and acute stress coping. <i>Biological Psychiatry</i> , 2012 , 71, 75-83	7.9	35
110	Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group. <i>Biochemical Journal</i> , 2012 , 444, 269-77	3.8	20
109	Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. <i>British Journal of Pharmacology</i> , 2012 , 166, 1586-99	8.6	155
108	3,6'-Dithiothalidomide, a new TNF- β synthesis inhibitor, attenuates the effect of A β -42 intracerebroventricular injection on hippocampal neurogenesis and memory deficit. <i>Journal of Neurochemistry</i> , 2012 , 122, 1181-92	6	52
107	Tumor necrosis factor- β synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2012 , 9, 106	10.1	140
106	Early intervention with a small molecule inhibitor for tumor necrosis factor- β prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2012 , 9, 99	10.1	70
105	Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. <i>PLoS ONE</i> , 2012 , 7, e32008	3.7	83

104	The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression. <i>Parkinson's Disease</i> , 2012 , 2012, 1423-72	2.6	29
103	Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid- β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 894-902	5.5	49
102	N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. <i>Current Alzheimer Research</i> , 2012 , 9, 746-58	3	191
101	Was phenserine a failure or were investigators misled by methods?. <i>Current Alzheimer Research</i> , 2012 , 9, 1174-81	3	11
100	Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012 , 11, 482-9	2.6	25
99	A synopsis on the role of tyrosine hydroxylase in Parkinson's disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012 , 11, 395-409	2.6	82
98	Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid- β peptide in mice. <i>Behavioural Brain Research</i> , 2011 , 225, 222-9	3.4	110
97	Thalidomide Analogues Suppress Lipopolysaccharide-Induced Synthesis of TNF- α and Nitrite, an Intermediate of Nitric Oxide, in a Cellular Model of Inflammation. <i>The Open Biochemistry Journal</i> , 2011 , 5, 37-44	0.9	21
96	Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs. <i>Journal of Alzheimer's Disease</i> , 2011 , 26, 143-55	4.3	24
95	Targets for AD treatment: conflicting messages from β secretase inhibitors. <i>Journal of Neurochemistry</i> , 2011 , 117, 359-74	6	49
94	Tumor necrosis factor- α synthesis inhibitor, 3,6'-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. <i>Journal of Neurochemistry</i> , 2011 , 118, 1032-42	6	81
93	The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. <i>Journal of Neural Transmission</i> , 2011 , 118, 493-507	4.3	47
92	Design, synthesis and biological assessment of novel N-substituted 3-(phthalimidin-2-yl)-2,6-dioxopiperidines and 3-substituted 2,6-dioxopiperidines for TNF- α inhibitory activity. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 3965-72	3.4	21
91	Extension of lifespan in <i>C. elegans</i> by naphthoquinones that act through stress hormesis mechanisms. <i>PLoS ONE</i> , 2011 , 6, e21922	3.7	64
90	Rivastigmine lowers A β and increases sAPP β levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. <i>PLoS ONE</i> , 2011 , 6, e21954	3.7	45
89	Targeting TNF- α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011 , 10, 391-403	2.6	150
88	Phenserine efficacy in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2010 , 22, 1201-8	4.3	45
87	Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia. <i>Journal of Neurochemistry</i> , 2010 , 112, 1316-26	6	141

86	Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. <i>Journal of Neurochemistry</i> , 2010 , 113, 1621-31	6	85
85	GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 1205-19	4.3	233
84	Lost in translation: neuropsychiatric drug development. <i>Science Translational Medicine</i> , 2010 , 2, 61rv6	17.5	39
83	Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010 , 334, 682-92	4.7	55
82	The KATP channel activator diazoxide ameliorates amyloid- β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2010 , 22, 443-57	4.3	84
81	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. <i>Bioorganic and Medicinal Chemistry</i> , 2010 , 18, 4687-93	3.4	24
80	GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 1285-90	11.5	414
79	Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions. <i>Biochemical Journal</i> , 2009 , 417, 213-22	3.8	26
78	Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element. <i>International Journal of Molecular Sciences</i> , 2009 , 10, 1226-60	6.3	61
77	Resurrecting clinical pharmacology as a context for Alzheimer disease drug development. <i>Current Alzheimer Research</i> , 2009 , 6, 79-81	3	6
76	Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. <i>Diabetes</i> , 2009 , 58, 318-28	0.9	135
75	A cellular model of inflammation for identifying TNF-alpha synthesis inhibitors. <i>Journal of Neuroscience Methods</i> , 2009 , 183, 182-7	3	37
74	Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's disease. <i>Journal of Chromatography A</i> , 2009 , 1216, 2730-8	4.5	32
73	Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. <i>Current Alzheimer Research</i> , 2008 , 5, 346-57	3	44
72	Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?. <i>Journal of Alzheimer's Disease</i> , 2008 , 15, 303-25	4.3	97
71	Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 289-98	1.9	43
70	Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. <i>Neurochemical Research</i> , 2008 , 33, 745-53	4.6	51
69	Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. <i>Journal of Neural Transmission</i> , 2008 , 115, 889-98	4.3	40

68	Dissociation Between the Potent β Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine 2008 , 445-462		1
67	Apoptotic and behavioral sequelae of mild brain trauma in mice. <i>Journal of Neuroscience Research</i> , 2007 , 85, 805-15	4.4	80
66	Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. <i>Journal of Neurochemistry</i> , 2007 , 100, 1421-9	6	108
65	Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease. <i>NeuroMolecular Medicine</i> , 2007 , 9, 157-68	4.6	12
64	Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 12506-11	11.5	72
63	The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 320, 386-96	4.7	103
62	TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. <i>Current Alzheimer Research</i> , 2007 , 4, 378-85	3	152
61	Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. <i>Experimental Neurology</i> , 2007 , 203, 293-301	5.7	147
60	Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 321, 353-61	4.7	11
59	Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in alzheimer disease 2007 , 9, 157		1
58	A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. <i>Current Alzheimer Research</i> , 2006 , 3, 81-90	3	54
57	Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 318, 855-62	4.7	36
56	Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 2174-85	8.3	64
55	Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2006 , 1760, 200-6	4	23
54	Neurine, an acetylcholine autolysis product, elevates secreted amyloid-beta protein precursor and amyloid-beta peptide levels, and lowers neuronal cell viability in culture: a role in Alzheimer's disease?. <i>Journal of Alzheimer's Disease</i> , 2006 , 10, 9-16	4.3	10
53	Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. <i>Journal of Alzheimer's Disease</i> , 2006 , 10, 43-51	4.3	30
52	Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 986-94	8.3	47
51	Syntheses of tetrahydrofurobenzofurans and dihydromethanobenzodioxepines from 5-hydroxy-3-methyl-3H-benzofuran-2-one. Rearrangement and ring expansion under reductive conditions on treatment with hydrides. <i>Journal of Organic Chemistry</i> , 2005 , 70, 6171-6	4.2	17

50	Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 1919-29	8.3	62
49	In vivo biological activity of exendin (1-30). <i>Endocrine</i> , 2005 , 27, 1-9		14
48	Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. <i>Current Alzheimer Research</i> , 2005 , 2, 483-92	3	34
47	Cholinesterases: roles in the brain during health and disease. <i>Current Alzheimer Research</i> , 2005 , 2, 307-18		246
46	An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. <i>Current Alzheimer Research</i> , 2005 , 2, 281-90	3	99
45	Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. <i>Current Alzheimer Research</i> , 2005 , 2, 377-85	3	93
44	Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 17213-8	11.5	519
43	Presence of a "CAGA box" in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer's disease. <i>FASEB Journal</i> , 2004 , 18, 1288-90	0.9	41
42	New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1035, 290-315	6.5	76
41	Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. <i>Experimental Neurology</i> , 2004 , 190, 133-44	5.7	43
40	Lethal weapon: amyloid beta-peptide, role in the oxidative stress and neurodegeneration of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004 , 25, 581-7	5.6	21
39	Acetylcholinesterase and its inhibition in Alzheimer disease. <i>Clinical Neuropharmacology</i> , 2004 , 27, 141-9	1.4	89
38	A new Alzheimer's disease interventive strategy: GLP-1. <i>Current Drug Targets</i> , 2004 , 5, 565-71	3	90
37	Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. <i>Current Drug Targets</i> , 2004 , 5, 517-28	3	53
36	Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. <i>Acta Neurobiologiae Experimentalis</i> , 2004 , 64, 1-9	1	27
35	A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. <i>Current Drug Targets</i> , 2003 , 4, 97-112	3	170
34	p53 is present in synapses where it mediates mitochondrial dysfunction and synaptic degeneration in response to DNA damage, and oxidative and excitotoxic insults. <i>NeuroMolecular Medicine</i> , 2003 , 3, 159-72	4.6	61
33	Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. <i>Journal of Neuroscience Research</i> , 2003 , 72, 603-12	4.4	269

32	Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 5222-9	8.3	70
31	The glucagon-like peptides: a double-edged therapeutic sword?. <i>Trends in Pharmacological Sciences</i> , 2003 , 24, 377-83	13.2	90
30	The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. <i>Regulatory Peptides</i> , 2003 , 114, 153-8		49
29	Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. <i>Diabetes Care</i> , 2003 , 26, 2835-41	14.6	92
28	p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. <i>Annals of Neurology</i> , 2002 , 52, 597-606	9.4	178
27	Current drug targets for Alzheimer's disease treatment. <i>Drug Development Research</i> , 2002 , 56, 267-281	5.1	146
26	Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. <i>International Psychogeriatrics</i> , 2002 , 14 Suppl 1, 77-91	3.4	259
25	Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. <i>NeuroMolecular Medicine</i> , 2002 , 1, 1-31	4.6	147
24	Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 302, 881-8	4.7	277
23	An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. <i>Journal of Biological Chemistry</i> , 2002 , 277, 45518-28	5.4	395
22	A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 300, 958-66	4.7	234
21	The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2002 , 4, 487-96	4.3	70
20	Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 5090-7	8.3	95
19	A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. <i>Journal of Neurochemistry</i> , 2001 , 77, 220-8	6	297
18	Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent. <i>Endocrinology</i> , 2001 , 142, 4462-8	4.8	25
17	Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. <i>Journal of Medicinal Chemistry</i> , 2001 , 44, 4062-71	8.3	74
16	Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. <i>Biochemical Pharmacology</i> , 2000 , 60, 561-70	6	47
15	Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. <i>Endocrinology</i> , 2000 , 141, 1936-41	4.8	248

14	Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 1855-61	8.3	182
13	Syntheses and anticholinesterase activities of (3aS)-N1, N8-bisnorphenserine, (3aS)-N1,N8-bisnorphysostigmine, their antipodal isomers, and other potential metabolites of phenserine. <i>Journal of Medicinal Chemistry</i> , 1998 , 41, 2371-9	8.3	26
12	Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine. <i>Biochemical and Biophysical Research Communications</i> , 1998 , 248, 180-5	3.4	32
11	Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 2895-901	8.3	50
10	Cognitive enhancement. New strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems. <i>Annals of the New York Academy of Sciences</i> , 1996 , 786, 348-61	6.5	37
9	Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. <i>NeuroReport</i> , 1995 , 6, 481-4	1.7	43
8	Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. <i>Medicinal Research Reviews</i> , 1995 , 15, 3-31	14.4	171
7	Total Synthesis of Racemic and Optically Active Compounds Related to Physostigmine and Ring-C Heteroanalogues from 3-[2?-(dimethylamino)ethyl]2,3-dihydro-5-methoxy-1,3-dimethyl-1H-indol-2-ol. <i>Helvetica Chimica Acta</i> , 1994 , 77, 1412-1422	2	15
6	Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis. <i>Life Sciences</i> , 1994 , 55, 2037-49	6.8	53
5	GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. <i>Pharmacology Biochemistry and Behavior</i> , 1991 , 40, 387-97	3.9	105
4	Physovenines: Efficient Synthesis of (±) and (+)-Physovenine and Synthesis of Carbamate Analogues of (±)Physovenine. Anticholinesterase Activity and Analgesic Properties of Optically Active Physovenines. <i>Helvetica Chimica Acta</i> , 1991 , 74, 761-766	2	32
3	Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. <i>Cancer Chemotherapy and Pharmacology</i> , 1990 , 26, 263-8	3.5	84
2	Tight binding dopamine reuptake inhibitors as cocaine antagonists. A strategy for drug development. <i>FEBS Letters</i> , 1989 , 257, 341-4	3.8	46
1	Optimizing drug delivery to brain tumors. <i>Cancer Treatment Reviews</i> , 1987 , 14, 1-28	14.4	108